Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Cancers
Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma
Data

Cancers·Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma

DataMismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma

Back to the Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma hub →51 connected records

Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.

Overview Types and stages Symptoms and diagnosis Treatment Trials and papers Biology and targets Countries and centres Decisions and support Pipeline and open problems Data

Data

Related pages

51

Direct links plus the targets, companies, and technologies of this cancer's products.

Similar pages

Cancer
Pancreatic acinar cell carcinoma
Shares Eileen M. O'Reilly, Whipple procedure (pancreaticoduodenectomy), Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors, KRAS wild-type pancreatic ductal adenocarcinoma and the tags subtype-page, gastrointestinal.
Cancer
Advanced and metastatic small bowel adenocarcinoma
Shares Mismatch repair & microsatellite instability, Mismatch-repair deficient (MSI-high) colorectal cancer, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), KRAS and the tags subtype-page, gastrointestinal.
Cancer
Localised small bowel adenocarcinoma (stage I to III, resected)
Shares Whipple procedure (pancreaticoduodenectomy), Lynch syndrome, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Germline (hereditary) testing and the tags subtype-page, gastrointestinal.
Cancer
Borderline resectable pancreatic ductal adenocarcinoma
Shares Eileen M. O'Reilly, PRODIGE 24 / CCTG PA6, Whipple procedure (pancreaticoduodenectomy), KRAS G12C-mutant pancreatic ductal adenocarcinoma and the tags subtype-page, gastrointestinal.
Cancer
Metastatic and recurrent anal squamous cell carcinoma
Shares PD-L1, Nivolumab, PD-1, Pembrolizumab and the tags subtype-page, gastrointestinal.
Cancer
Pancreatoblastoma
Shares Whipple procedure (pancreaticoduodenectomy), Germline (hereditary) testing, KRAS, Pancreatic ductal adenocarcinoma and the tags subtype-page, gastrointestinal.
Cancer
Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell)
Shares Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), KRAS, Pembrolizumab, Cytotoxic chemotherapy and the tags subtype-page, gastrointestinal.
Cancer
Resectable pancreatic ductal adenocarcinoma
Shares Eileen M. O'Reilly, PRODIGE 24 / CCTG PA6, Whipple procedure (pancreaticoduodenectomy), Gemcitabine + nab-paclitaxel and the tags subtype-page, gastrointestinal.

technologies

Comprehensive genomic profiling Cytotoxic chemotherapy Germline (hereditary) testing Immune checkpoint inhibitors Off-the-shelf cancer vaccines Platinum agents Topoisomerase-I inhibitors (and ADC payloads)

targets

CTLA-4 KRAS PD-1 PD-L1

drugs

ApprovedMonoclonal antibody (anti-PD-1)

Dostarlimab · Jemperli

ApprovedCytotoxic regimen

FOLFIRINOX / mFOLFIRINOX

ApprovedCytotoxic regimen

Gemcitabine + nab-paclitaxel · Gemzar + Abraxane

ApprovedMonoclonal antibody (anti-CTLA-4)

Ipilimumab · Yervoy

ApprovedMonoclonal antibody (anti-PD-1)

Nivolumab · Opdivo / Opdivo Qvantig (SC)

ApprovedMonoclonal antibody (anti-PD-1)

Pembrolizumab · Keytruda / Keytruda Qlex (SC)

companies

Bristol Myers Squibb GSK Merck & Co. (MSD)

pathways

Cold tumours: immune deserts and exclusion Mismatch repair & microsatellite instability PD-1 / PD-L1 immune checkpoint & T-cell activation The cancer-immunity cycle

terms

Germline vs somatic mutations Lynch syndrome Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR)Microsatellite-stable (MSS) / mismatch-repair proficient (pMMR)Neoantigen Pancreatic cancer drugs in England: NICE appraisals and the Cancer Drugs Fund (September 2026)Tumour mutational burden (TMB)Whipple procedure (pancreaticoduodenectomy)

trials

Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI KEYNOTE-158 KEYNOTE-177 Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer PRODIGE 24 / CCTG PA6

ideas

Automatic germline testing for every cancer type where it changes care

people

Bert Vogelstein Dung T. Le Eileen M. O'Reilly Elizabeth M. Jaffee

key papers

Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications First trial of a vaccine against the shared neoantigens of mismatch-repair-deficient cancers Hu 2018: evaluating mismatch repair deficiency in pancreatic adenocarcinoma, challenges and recommendations KEYNOTE-158: pembrolizumab in non-colorectal high microsatellite instability or mismatch repair-deficient cancer Le 2017: mismatch-repair deficiency predicts response to PD-1 blockade across twelve tumour types, leading to the first tissue-agnostic drug approval Molecular characterization of KRAS wild-type tumors in patients with pancreatic adenocarcinoma Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers

biomarkers

dMMR (mismatch repair deficiency by IHC)MSI-high (microsatellite instability by PCR or sequencing)

Machine-readable versions

The same record for scripts and assistants; checked 2026-09-18. Data CC BY-NC 4.0, attribute “Data from OnCo (onco.cc)”.

JSON with neighbours Markdown context RDF Turtle Sections with routes and counts API root

ProvenanceLast edited 2026-09-22 · Jude Gomila · Every pancreatic subtype page now rests on two to four la… · diff · file

Wikipedia

Microsatellite instability

Sources & links

Wikipedia
NCCN Guidelines: Pancreatic Adenocarcinoma

subtype-page gastrointestinal

Data

JSON ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
How review works

Not yet reviewedNeeds expert (clinical) and patient advocate review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Machine-readable versions of Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/cancers/msi-high-pdac/)
Section plan: the ten sections of this record with routes, anchors and counts
All cancers as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id msi-high-pdac.

WebMCP tools registered on this page: onco_search, onco_get_entity.